Montreal Heart Institute
A major centre for the coordination of cardiology clinical trials in Canada
A highly specialized university hospital affiliated with the Université de Montréal, the Montreal Heart Institute (MHI) provides a full range of services for the conduct of phase I to IV clinical trials in healthy volunteers and patients.
Its Montreal Health Innovations Coordinating Centre (MHICC) is one of the largest in Canada and is globally recognized as a leader in this field. It boasts a 200-person team and state-of-the-art facilities serving the university community as well as the pharmaceutical, biotechnology and medical device industries. The MHICC is also home to 11 laboratories for the analysis of medical imaging modalities, all connected through a computer network (CAIN). The institution has put together one of the largest hospital cohorts in the world as well as a biobank, which makes it easier to meet recruitment targets and encourages innovation in clinical research through artificial intelligence tools.
Cardiology, metabolic diseases, cardiovascular disease prevention and risk factors, neurology, oncology, dermatology, endocrinology, gastroenterology and pharmacogenomics. More specifically: hypertension, cholesterol, diabetes, insulin resistance, obesity, cardiovascular genetics, cognitive disorders, dementia, sophisticated brain imaging, impacts of the microbiome on metabolic and cardiovascular health.
- Drug studies (including new chemical entities and natural health products), diagnostics and medical devices;
- Access to specific patient populations; for example, patients with cardiovascular or metabolic diseases;
- 20-bed short-stay unit, with medical staff, specialized nurse and 24/7 care, including urgent care;
- Core laboratory and imaging services: echocardiography, ultrasound, cardiac magnetic resonance (CMR) and computerized axial tomography;
- Operational oversight and expertise: central management, oversight, data management, statistical analysis, production of reports meeting regulatory quality standards and related to good clinical practices (GCP).
Investigateurs spécialisés en phase I
Dr. Philippe L’Allier – atherosclerosis, atherothrombosis, percutaneous interventions, plaque imaging (invasive methods), vascular inflammation, antiplatelets, vulnerable plaque, hypertrophic cardiomyopathy, percutaneous renal denervation for the treatment of cardiovascular pathologies
Dr. Denis Roy – cardiac arrhythmias, combination of arrhythmias and heart failure
Dr. André Denault – medical and surgical intensive care, hemodynamic instability, echocardiography and targeted ultrasound, pulmonary hypertension, right ventricular function
For further information
Dr. Andreas Orfanos, MBBCh, FFPM, MBA